by Flora Velle-Bonvouloir

At Citizen Capital, we believe that health is a fundamental need that technology and innovation can make more accessible and more equitable — for patients and healthcare professionals alike. By investing in Sêmeia, the French leader in remote patient monitoring, we are backing a model that combines proven clinical impact, organisational benefits for the healthcare system, and reduced inequalities in access to care.

Sêmeia’s impact in numbers:

• 4 active therapeutic areas, with new pathologies currently being deployed
• 35,000 patients covered across approximately 500 healthcare facilities
• 110,000 health data points collected monthly
• 27% of monitored patients live in medical deserts

A healthcare system under pressure: the urgency to act

By 2035, chronic diseases could affect up to 16 million patients in France and account for 75% of healthcare spending. At the same time, the medical workforce is shrinking, medical deserts are deepening, and healthcare professionals are carrying an ever-growing administrative burden.
Remote patient monitoring has emerged in this context as a structural lever: it facilitates the follow-up of patients at a distance, preventing complications, reducing avoidable hospitalisations, relieving care teams and optimising care pathways — without adding burden on patients or practitioners.
This is exactly what Sêmeia has been building since its founding in 2017 in Toulouse. Its digital medical device MedicWise is a platform for the automated collection, structuring and restitution of outpatient health data. Designed with healthcare professionals to integrate naturally into their practices, it transforms patient data streams into targeted clinical alerts.
The MedicWise platform is already deployed across more than 500 healthcare facilities, serving more than 35,000 patients in nephrology, cardiology and mental health.

An investment to reach the next stage

In May 2026, Sêmeia completed a fundraise of 21 million euros with Acton Capital, Mutuelles Impact and Citizen Capital, alongside its existing investors Banque des Territoires and Orange Ventures.
These resources will fund the expansion of MedicWise to new pathologies through new clinical studies, the strengthening of AI innovation capabilities, and the continuation of an already active external growth strategy (Optim’Care in 2022 and Healabs in 2025).
We are proud to support a team that has demonstrated that a health technology can be medically rigorous, reimbursed and scalable — all at once.

A triple value proposition

Sêmeia’s strength lies in its ability to address three distinct needs simultaneously:

For the healthcare system, it reduces avoidable hospitalisations and optimises the organisation of care teams.
For prescribing physicians, it provides decision-support tools grounded in reliable, structured data — with no added workload.
For patients, it improves day-to-day monitoring, treatment adherence, care quality and, ultimately, quality of life.

This triple value proposition explains both the robustness of Sêmeia’s business model — whose tool has obtained reimbursement from the French national health insurance — and the depth of its impact.

Demonstrated clinical and organisational impact

In nephrology, where the solution is a benchmark, results from controlled studies are compelling: −26% hospitalisations for patients under remote monitoring, and 73% of physician time saved through automated data collection and targeted alert generation.
In psychiatry, early results are equally significant: for bipolar patients under monitoring, studies show −50% suicide attempts and −41% emergency hospitalisations.

Reducing medical deserts

27% of patients monitored by Sêmeia live in medical deserts. This figure is not incidental: it concretely illustrates how technology can act as a driver of territorial equity in access to care.
By enabling quality remote monitoring — without systematic travel or unnecessary consultations — Sêmeia helps reduce geographical inequalities, one of the deepest fractures in our healthcare system.

Our conviction

The team led by Pierre Hornus has built a solution that is medically rigorous, technologically robust and economically viable. They have demonstrated, pathology by pathology, that remote patient monitoring is not a bet on the future: it is an operational, validated and reimbursed tool that concretely improves patients’ lives and the organisation of care.
This is precisely the dual ambition we champion at Citizen Capital: aligning economic performance with real, measurable and lasting impact — in the service of those whose health also depends on the quality of the system that supports them.